Ersin MUHAFIZ, Seray Aslan BAYHAN, Hasan Ali BAYHAN, Emine ÇÖLGEÇEN, Canan GÜRDAL

EVALUATION OF MEIBOMIAN GLANDS IN CUTANEOUS ROSACEA

Objective To evaluate tear functions and Meibomian glands’ status in patients with cutaneous rosacea. Material and Methods Right eyes of 38 patients with cutaneous rosacea (study group) and 30 healthy volunteers (control group) were evaluated. After Ocular Surface Disease Index (OSDI) score was calculated, tear osmolarity and tear break-up time (T-BUT) were measured, and the Schirmer test was applied respectively. Meibomian glands in the lower and upper eyelids were evaluated by meibography using the Sirius anterior segment analysis system. Results No statistically significant difference was detected between the groups in respect of age and gender (p>0.05). No statistically significant difference was determined between the groups in respect of the OSDI score, tear osmolarity, and Schirmer test values (p>0.05 for all). The T-BUT values of the study group were detected to be significantly shorter than those of the control group (p

CİLT ROZASEASINDA MEİBOMİAN BEZLERİN DEĞERLENDİRİLMESİ

Amaç Cilt rozaseası olan hastalarda gözyaşı fonksiyonlarını ve Meibomian bezlerin durumunu değerlendirmek. Gereç ve Yöntem Cilt rozaseası olan 38 hasta (çalışma grubu) ile 30 sağlıklı gönüllü bireyin (kontrol grubu) sağ gözleri değerlendirildi. Oküler yüzey hastalık indeksi (OSDI) skoru hesaplandıktan sonra sırasıyla gözyaşı ozmolariteleri ve gözyaşı kırılma zamanları (T-BUT) ölçülüp ve Schirmer testi yapıldı. Alt ve üst kapaktaki meibomian bezler Sirius ön segment analiz sistemi ile meibografi yapılarak değerlendirildi. Bulgular Gruplar arasında yaş ve cinsiyet açısından istatistiksel olarak anlamlı fark saptanmadı (p>0.05). OSDI skoru, gözyaşı ozmolaritesi ve Schirmer değerleri açısından gruplar arasında istatistiksel olarak anlamlı fark saptanmadı (tümü için p>0.05). Çalışma grubunun T-BUT değerlerinin kontrol grubuna göre anlamlı olarak daha kısa olduğu tespit edildi (p

PDF

___

1. Steinhoff M, Schauber J, Leyden JJ. New insights into rosacea pathophysiology: a review of recent findings. J Am Acad Dermatol 2013;69:5–26.

2. Gallo RL, Granstein RD, Kang S, Mannis M, Steinhoff M, Tan J, Thiboutot D. Standard classification and pathophysiology of rosacea: The 2017 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol 2018;78:148-155.

3. Spoendlin J, Voegel JJ, Jick SS, Meier CR. A study on the epidemiology of rosacea in the U.K. Br J Dermatol 2012;167:598- 605.

4. Webster G, Schaller M. Ocular rosacea: a dermatologic perspective. J Am Acad Dermatol 2013;69:42–43.

5. Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol 2004;51:327–341.

6. Awais M, Anwar MI, Iftikhar R, Iqbal Z, Shehzad N, Akbar B. Rosacea—the ophthalmic perspective. Cutan Ocul Toxicol 2015;34:161-166.

7. Blount BW, Pelletier AL. Rosacea: a common, yet commonly overlooked, condition. Am Fam Physician 2002;66:435-440.

8. Vieira AC, Höfling-Lima AL, Mannis MJ. Ocular rosacea-a review. Arq Bras Oftalmol 2012;75:363–369.

9. Oltz M, Check J. Rosacea and its ocular manifestations. Optometry 2011;82:92–103.

10. Wilkin J, Dahl M, Detmar M, Drake L, Liang MH, Odom R, Powell F. Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol 2004;50:907-912.

11. Ghanem VC, Mehra N, Wong S, Mannis MJ. The prevalence of ocular signs in acne rosacea: comparing patients from ophthalmology and dermatology clinics. Cornea 2003;22:230-233.

12. Dursun Altınörs D, Asena L. Systemic Diseases and Dry Eye. MN Oftalmoloji 2016;23:53-59.

13. Knop E, Knop N, Millar T, Obata H, Sullivan DA. The international workshop on meibomian gland dysfunction: report of the subcommittee on anatomy, physiology, and pathophysiology of the meibomian gland. Invest Ophthalmol Vis Sci 2011; 52:1938-1978.

14. Arita R, Itoh K, Inoue K, Amano S. Noncontact infrared meibography to document age-related changes of the meibomian glands in a normal population. Ophthalmology 2008;115:911–915.

15. Palamar M, Değirmenci C, Ertam I, Yağci A. Evaluation of dry eye and meibomian gland dysfunction with meibography in patients with rosacea. Cornea 2015;34:497–499.

16. Holmes AD. Potential role of microorganisms in the pathogenesis of rosacea. J Am Acad Dermatol 2013;69:1025–1032.

17. Müftüoglu İK, Aydın Akova Y. Clinical Findings, Follow-up and Treatment Results in Patients with Ocular Rosacea. Turk J Ophthalmol 2016;46:1-6.

18. Evren Ö, Karci AA, Orhan İ, Artüz F, Tamer U, Sener B, Gürsel E. Tear Film Function and Lipid Composition of Meibomian Glands. Turk J Ophthalmol 2006;36:450-456.

19. Alvarenga LS, Mannis MJ. Ocular rosacea. Ocul Surf 2005;3:41–58.

20. Adil MY, Xiao J, Olafsson J, Chen X, Lagali NS, Ræder S, Utheim ØA, Dartt DA, Utheim TP. Meibomian Gland Morphology Is a Sensitive Early Indicator of Meibomian Gland Dysfunction. Am J Ophthalmol 2019;200:16-25.

21. Machalińska A, Zakrzewska A, Markowska A, Safranow K, Wiszniewska B, Parafiniuk M, Machaliński B. Morphological and Functional Evaluation of Meibomian Gland Dysfunction in Rosacea Patients. Curr Eye Res 2016;41:1029-1034.

22. Lee WJ, Jung JM, Lee YJ, et al. Histopathological Analysis of 226 Patients With Rosacea According to Rosacea Subtype and Severity. Am J Dermatopathol 2016; 38: 347-352.

23. Liang H, Randon M, Michee S, Tahiri R, Labbe A, Baudouin C. In vivo confocal microscopy evaluation of ocular and cutaneous alterations in patients with rosacea. Br J Ophthalmol 2017;101:268-2674.

24. Schaller M, Almeida LM, Bewley A, Cribier B, Dlova NC, Kautz G, Mannis M, Oon HH, Rajagopalan M, Steinhoff M, Thiboutot D, Troielli P, Webster G, Wu Y, van Zuuren E, Tan J. Rosacea treatment update: recommendations from the global ROSacea COnsensus (ROSCO) panel. Br J Dermatol. 2017;176:465- 471.

25. Andrade FMX, Picosse FR, Cunha LPD, Valente CM, Bezerra FM, Miot H, Bagatin E, Freitas D. Ocular surface changes in the treatment of rosacea: comparison between low-dose oral isotretinoin and doxycycline. Arq Bras Oftalmol. 2020;83:109-112.

26. Holzchuh FG, Hida RY, Moscovici BK, Villa Albers MB, Santo RM, Kara-José N, Holzchuh R. Clinical treatment of ocular Demodex folliculorum by systemic ivermectin. Am J Ophthalmol. 2011;151:1030-1034.e1.

27. Sobolewska B, Doycheva D, Deuter CM, Schaller M, Zierhut M. Efficacy of Topical Ivermectin for the Treatment of Cutaneous and Ocular Rosacea. Ocul Immunol Inflamm. 2020:1-5. Epub ahead of print. PMID: 32255398.

28. Ozek D, Evren Kemer Ö, Artüz F. Assessment of Tear Functions in Patients with Acne Rosacea without Meibomian Gland Dysfunction. Ocul Immunol Inflamm 2019;27:632-635.

29. Topcu-Yilmaz P, Atakan N, Bozkurt B, Irkec M, Aban D, Mesci L, Tezcan I. Determination of tear and serum inflammatory cytokines in patients with rosacea using multiplexbead technology. Ocul Immunol Inflamm 2013;21:351-359.